Eliquis scores DVT/PE recommendation in Europe

Carly Helfand

Right now, , the new-age clot-fighter from Pfizer and Bristol-Myers Squibb, is in third place in a three-horse race. But as it tries to catch up to rivals Pradaxa and Xarelto–not to mention the $ 3-billion-per-year sales forecasts analysts slapped on it in its early days–a new for expanded use in should give it a boost.

FiercePharma News

Share This Post

Related Articles

Leave a Reply

© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS